| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | | | | Searchterm 'T2' was also found in the following services: | | | | |
| | |
| |
|
Contrast agents are chemical substances introduced to the anatomical or functional region being imaged, to increase the differences between different tissues or between normal and abnormal tissue, by altering the relaxation times. MRI contrast agents are classified by the different changes in relaxation times after their injection.
•
Negative contrast agents (appearing predominantly dark on MRI) are small particulate aggregates often termed superparamagnetic iron oxide ( SPIO). These agents produce predominantly spin spin relaxation effects (local field inhomogeneities), which results in shorter T1 and T2 relaxation times.
SPIO's and ultrasmall superparamagnetic iron oxides ( USPIO) usually consist of a crystalline iron oxide core containing thousands of iron atoms and a shell of polymer, dextran, polyethyleneglycol, and produce very high T2 relaxivities. USPIOs smaller than 300 nm cause a substantial T1 relaxation. T2 weighted effects are predominant.
•
A special group of negative contrast agents (appearing dark on MRI) are perfluorocarbons ( perfluorochemicals), because their presence excludes the hydrogen atoms responsible for the signal in MR imaging.
The design objectives for the next generation of MR contrast agents will likely focus on prolonging intravascular retention, improving tissue targeting, and accessing new contrast mechanisms. Macromolecular paramagnetic contrast agents are being tested worldwide. Preclinical data shows that these agents demonstrate great promise for improving the quality of MR angiography, and in quantificating capillary permeability and myocardial perfusion.
Ultrasmall superparamagnetic iron oxide ( USPIO) particles have been evaluated in multicenter clinical trials for lymph node MR imaging and MR angiography, with the clinical impact under discussion. In addition, a wide variety of vector and carrier molecules, including antibodies, peptides, proteins, polysaccharides, liposomes, and cells have been developed to deliver magnetic labels to specific sites. Technical advances in MR imaging will further increase the efficacy and necessity of tissue-specific MRI contrast agents.
See also Adverse Reaction and Nephrogenic Systemic Fibrosis.
See also the related poll result: ' The development of contrast agents in MRI is' | | | | | | | | | | | | | | | | Further Reading: | | Basics:
|
|
News & More:
| |
Brain imaging method may aid mild traumatic brain injury diagnosis Tuesday, 16 January 2024 by parkinsonsnewstoday.com | | |
A Targeted Multi-Crystalline Manganese Oxide as a Tumor-Selective Nano-Sized MRI Contrast Agent for Early and Accurate Diagnosis of Tumors Thursday, 18 January 2024 by www.dovepress.com | | |
FDA Approves Gadopiclenol for Contrast-Enhanced Magnetic Resonance Imaging Tuesday, 27 September 2022 by www.pharmacytimes.com | | |
How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol Saturday, 5 February 2022 by www.ncbi.nlm.nih.gov | | |
Estimation of Contrast Agent Concentration in DCE-MRI Using 2 Flip Angles Tuesday, 11 January 2022 by pubmed.ncbi.nlm.nih.gov | | |
Manganese enhanced MRI provides more accurate details of heart function after a heart attack Tuesday, 11 May 2021 by www.news-medical.net | | |
Gadopiclenol: positive results for Phase III clinical trials Monday, 29 March 2021 by www.pharmiweb.co | | |
Gadolinium-Based Contrast Agents Hypersensitivity: A Case Series Friday, 4 December 2020 by www.dovepress.com | | |
Polysaccharide-Core Contrast Agent as Gadolinium Alternative for Vascular MR Monday, 8 March 2021 by www.diagnosticimaging.com | | |
Water-based non-toxic MRI contrast agents Monday, 11 May 2020 by chemistrycommunity.nature.com | | |
New method to detect early-stage cancer identified by Georgia State, Emory research team Friday, 7 February 2020 by www.eurekalert.org | | |
Researchers Brighten Path for Creating New Type of MRI Contrast Agent Friday, 7 February 2020 by www.newswise.com | | |
Manganese-based MRI contrast agent may be safer alternative to gadolinium-based agents Wednesday, 15 November 2017 by www.eurekalert.org | | |
Sodium MRI May Show Biomarker for Migraine Friday, 1 December 2017 by psychcentral.com | | |
A natural boost for MRI scans Monday, 21 October 2013 by www.eurekalert.org | | |
For MRI, time is of the essence A new generation of contrast agents could make for faster and more accurate imaging Tuesday, 28 June 2011 by scienceline.org |
|
| |
| | | | | |
| |
|
In fast imaging sequences driven equilibrium sensitizes the sequence to variations in T2. This MRI technique turns transverse magnetization Mxy to the longitudinal axis using a pulse rather than waiting for T1 relaxation.
The first two pulses form a spin echo and, at the peak of the echo, a second 90° pulse returns the magnetization to the z-axis in preparation for a fresh sequence.
In the absence of T2 relaxation, then all the magnetization can be returned to the z-axis. Otherwise, T2 signal loss during the sequence will reduce the final z-magnetization.
The advantage of this sequence type is, that both longitudinal and also transverse magnetization are back to equilibrium in a shorter amount of time. Therefore, contrast and signal can be increased while using a shorter TR. This pulse type can be applied to other sequences like FSE, GE or IR.
Sequences with driven equilibrium:
Driven Equilibrium Fast Gradient Recalled acquisition in the steady state - DE FGR,
Driven Equilibrium Fourier Transformation - DEFT,
Driven Equilibrium magnetization preparation - DE prep,
Driven Equilibrium Fast Spin Echo - DE FSE. | | | | | | • View the DATABASE results for 'Driven Equilibrium' (8).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
Some dyamides are under preclinical development as intravascular MRI contrast agents for blood flow perfusion.
Short name: Dy-DTPA-BMA, generic name: Sprodyamide, central moiety: Dy2+, contrast effect: T2*enhanced, relaxivity: r1=3.4, r2=3.8, B0=0.47,
Short name: Dy-DTPA, central moiety: Dy2+, contrast effect: T2*enhanced,
Short name: Albumin-(Dy-DTPA)x, central moiety: Dy2+, contrast effect: T2*enhanced.
| | | | | Further Reading: | Basics:
|
|
| |
| | | Searchterm 'T2' was also found in the following services: | | | | |
| | |
| |
|
| | | | | | • View the DATABASE results for 'Fast Imaging with Steady Precession' (3).
| | | | Further Reading: | Basics:
|
|
| |
| | | | | | | | | |
| | | |
|
| |
| Look Ups |
| |